1 active not recruiting, 1 completed, 1 suspended, 1 unknown. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Suspended 1, Unknown 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Apollomics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants APL-101, PLB-1001 - Bioequivalence | Phase 1 | Unknown | Apollomics Inc. | 48 | 2022-05-20 | 2022-06-15 |
| Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) APL-101, Osimertinib - Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 27 | 2022-01-18 | 2026-01-20 |
| APL-102 Capsule in Patients With Advanced Solid Tumors APL-102 Capsules - Advanced Solid Tumor | Phase 1 | Suspended | Apollomics Inc. | 30 | 2021-08-02 | 2025-06-27 |
| Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Uproleselan - Relapsed/Refractory AML | Phase 1 | Completed | Apollomics Inc. | 12 | 2021-02-24 | 2025-06-27 |
Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Myeloid, Acute (1)
osimertinib (1) · uproleselan (1)
China (2) · New Zealand (1) · United States (1)
Anjali Rohatgi, M.D., Ph.D. (1) · Jianxiang Wang, PhD (1) · Marietta Franco, MS (1) · Yihebali Chi, PhD (1)